Prne
June 29th, 2009
SAN DIEGO -
- Results Demonstrate Positive Proof of Mechanism
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor.
The interim results demonstrate that a sustained pharmacodynamic (PD) effect can be achieved with a single dose of AM211. The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species. While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
“The AM211 clinical PD data confirms what we previously observed in pre-clinical models,” said Isabelle DeArmond, M.D., Vice President, Clinical Development. “While a great deal of clinical work remains on this program, we are particularly excited since we believe DP2 antagonism would be a novel therapeutic approach to various respiratory diseases.”
Bob Baltera, Chief Executive Officer, added, “Once again the Amira team demonstrates our ability to quickly, efficiently and accurately translate scientific efforts into meaningful therapeutic candidates. The fact that we now have clinical data only 25 months after we initiated scientific efforts on this target in our laboratories is a source of pride for the entire Amira team.”
About Amira
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.
Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.
Media Contact Ian Stone Russo Partners Tel: +1-619-528-2220 ian.stone@russopartnersllc.com
Source: Amira Pharmaceuticals, Inc.
Ian Stone of Russo Partners for Amira Pharmaceuticals, Inc., +1-619-528-2220, ian.stone at russopartnersllc.com
Filed under Clinical Trials / Medical Discoveries, Health, Health Care / Hospitals, Pharmaceuticals | Tags: Amira Pharmaceuticals, california, denmark, Fact, Inc., San diego, Western Europe | Comment Below
Related Press Releases Karolinska Development Portfolio Company Completes Successful Phase II Clinical TrialSeptember 3rd, 2009 STOCKHOLM - Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 17th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461August 17th, 2009 SAN DIEGO -
Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in NocturiaJune 28th, 2009 SOUTHAMPTON, England - Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research ConferenceJune 14th, 2009 SAN DIEGO - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona. Invitation: PROSTVAC(TM) Wrap upMay 26th, 2009 KVISTGAARD, Denmark - Following the presentation of data with PROSTVAC(TM) - a promising, late-stage vaccine candidate for the treatment of advanced prostate cancer, Bavarian Nordic will be hosting a Q&A session at the ASCO Annual Meeting. Time: Sunday, May 31st 2009 from 09 AM EDT to 10 AM EDT. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) InhibitorMay 12th, 2009 NERVIANO, Italy - The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells. PRA International: Participating Sponsor for Exploratory Clinical Development World in LondonMay 11th, 2009 RALEIGH, North Carolina - PRA International, a leading Clinical Research Organization, announces it is participating as a sponsor for Exploratory Clinical Development World (ECDW), 13-14 May 2009, in London, UK. ECDW is considered to be Europe's largest and most highly regarded early development congress. Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With GlaucomaMay 5th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA). Amira Initiates Phase I Clinical Trial of Novel DP2 AntagonistApril 19th, 2009 SAN DIEGO - Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD
Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway. AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis.
Related News Don't want a cold? Get a face maskJanuary 27th, 2009 SYDNEY - Donning a face mask is the best bet against respiratory infections like influenza and the common cold, according to a new study. In the first ever clinical trial of its kind, University of New South Wales (UNSW) researchers found adult mask wearers at home were four times more likely than non-wearers to be protected against respiratory viruses, including the common cold. Fast acting erectile disorder drug goes on trial againFebruary 15th, 2009 WASHINGTON - A new fast-acting oral drug for erectile dysfunction (ED) is ready for a crucial trial phase. It's going to be a multicentre, randomised, double-blind, placebo-controlled trial that will evaluate the safety and efficacy of Avanafil in the treatment of ED in men with type-1 or type-2 diabetes. Novel target for migraine prevention identifiedApril 29th, 2009 WASHINGTON - Researchers have found a potential target for developing new treatment for acute migraine attacks. The new research by Addex Pharmaceuticals showed that targeting glutamate receptor 'mGluR5', the most common neurotransmitter in the brain, could prevent migraines. Indian clinical research company to set-up unit in Kuala LumpurJuly 27th, 2009 NEW DELHI - The Ahmedabad-based Veeda Clinical Research organization is entering Malaysia's medical sector by setting up its advanced research unit at the Ampang Hospital in Kuala Lumpur by the year-end. India's fastest-growing clinical research organisation has selected the Ampang Hospital to conduct first phase clinical trials on humans under a quasi-commercial agreement with the Malaysian Health Ministry, The Star Online reports. MakroCare announces workshop on Advanced GCP on May 15May 6th, 2009 HYDERABAD - MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries, is taking a lead in the training of professionals for the clinical research industry by providing series of informational through workshop and seminars. Advanced GCP workshop will be held at CHITRAMAYEE Auditorium, State Arts Gallery, Kavuri Hills, Madhapur, Hyderabad on May 15. GVK Biosciences forms clinical research alliance with Excel PharmaStudiesApril 14th, 2009 HYDERABAD - GVK Biosciences (GVK BIO), Asia's leading integrated research services provider and Excel PharmaStudies (Excel), a leading Chinese Clinical Research Organization announced a strategic alliance to conduct clinical trials in Asia. The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China. New device may make menstrual cramp pain 'history'September 22nd, 2009 WASHINGTON - For women who experience severe menstrual pain, a new device developed by University of Cincinnati researchers could appear as a blessing. Fed up of the chronic pain, women often end up having medications that can cause gastrointestinal side effects. Indian-origin scientist designs mathematical model to heal toughest of woundsSeptember 22nd, 2009 WASHINGTON - Researchers at Ohio State University, led by an Indian-origin scientist, have developed a mathematical model of chronic wound healing that could do away with guesswork and clearly suggest treatment strategies towards tackling a major public-health problem. The researchers are the first to publish a mathematical model of an ischemic wound - a chronic wound that heals slowly or is in danger of never healing because it is fed by an inadequate blood supply. Face masks could protect against swine flu pandemicApril 28th, 2009 SYDNEY - Donning a face-mask is an easy way to protect oneself from severe respiratory illnesses like swine flu when vaccines are unavailable or in short supply, according to a study. In the first ever clinical trial of the efficacy of masks, researchers found adult mask wearers at home were four times more likely than non-wearers to be protected against a range of respiratory viruses, including influenza, SARS and even the common cold. Scientists searching for specific genes related to happinessJune 24th, 2009 WASHINGTON - A Tel Aviv University researcher in Israel is trying to identify specific genes that are associated with happiness. Prof. Yoram Barak of the university's Sackler School of Medicine has joined forces with researchers at the Chaim Sheba Medical Centre at Tel Hashomer, which is the largest hospital in Israel, for the purpose.
|
|
